Dr. Hébert was born in Montréal in 1974. He studied biotechnology, and obtained his Ph.D. in Cellular and Molecular Biology at Laval University in 2003. He then completed a postdoctoral fellowship in human genetics at the Katholieke Universiteit Leuven in Belgium. In 2009, he was recruited as Assistant Professor at Laval University. Dr. Hébert is currently an Associate Professor in the Department of Psychiatry and Neuroscience at Laval University. He is also a researcher (group leader) in the Neuroscience Unit of the Research Center of the CHU de Québec – Laval University.

Dr. Hébert’s work focuses on the biological and molecular mechanisms that cause neuronal death and dementia. Specifically, his research team studies the role of micro-RNAs in the development, diagnosis, and treatment of neurodegenerative diseases such as Alzheimer’s disease, frontotemporal dementia, and Huntington’s disease. Micro-RNAs are small molecules in the body that are similar to DNA and regulate the level of proteins. Dr. Hébert’s pioneering research has shown that many micro-RNAs are deregulated in patients with Alzheimer’s disease, and other types of dementia. Curiously, a number of these molecules can reproduce the pathological and clinical symptoms of dementia in biological models on their own, such as cultured neurons and mice. Dr. Hébert also uses the postmortem human brain as an indispensable tool for his research.

Recently, his work on a potential treatment for Alzheimer’s disease was presented by Le Soleil, the FM93 radio station, and The Alzheimer’s Society of Canada’s Website.

Dr. Hébert has received various awards, including the Alzheimer’s Society of Saskatchewan’s Young Investigator Grant (2010) and the FRQS Junior Research Scholar Career Award (2011, 2014). He has been a spokesperson for the Alzheimer’s Society of Canada (2011). In addition to his commitment to teaching, he regularly participates in various evaluation committees and conferences. Finally, he helps organize events and promote basic Canadian research on Alzheimer’s disease, and related dementias.

CHUL
2705, boulevard Laurier
P-0-9800
Québec, Québec
Canada G1V 4G2

Latest news

Data not available

60 entries « 1 of 12 »

Wang X, Liu D, Huang HZ, Wang ZH, Hou TY, Yang X, Pang P, Wei N, Zhou YF, Dupras MJ, Calon F, Wang YT, Man HY, Chen JG, Wang JZ, Hebert SS, Lu Y, Zhu LQ

A Novel MicroRNA-124/PTPN1 Signal Pathway Mediates Synaptic and Memory Deficits in Alzheimer's Disease.

Journal Article

Biol Psychiatry, 83 (5), pp. 395-405, 2018, ISSN: 0006-3223.

Abstract | Links:

St-Amour I, Turgeon A, Goupil C, Planel E, Hebert SS

Co-occurrence of mixed proteinopathies in late-stage Huntington's disease.

Journal Article

Acta Neuropathol, 135 (2), pp. 249-265, 2018, ISSN: 0001-6322.

Abstract | Links:

Hui CW, St-Pierre A, El Hajj H, Remy Y, Hebert SS, Luheshi GN, Srivastava LK, Tremblay ME

Prenatal Immune Challenge in Mice Leads to Partly Sex-Dependent Behavioral, Microglial, and Molecular Abnormalities Associated with Schizophrenia.

Journal Article

Front Mol Neurosci, 11 , pp. 13, 2018.

Abstract | Links:

Liu D, Tang H, Li XY, Deng MF, Wei N, Wang X, Zhou YF, Wang DQ, Fu P, Wang JZ, Hebert SS, Chen JG, Lu Y, Zhu LQ

Targeting the HDAC2/HNF-4A/miR-101b/AMPK Pathway Rescues Tauopathy and Dendritic Abnormalities in Alzheimer's Disease.

Journal Article

Mol Ther, 25 (3), pp. 752-764, 2017, ISSN: 1525-0016.

Abstract | Links:

Olde Loohuis NF, Nadif Kasri N, Glennon JC, van Bokhoven H, Hebert SS, Kaplan BB, Martens GJ, Aschrafi A

The schizophrenia risk gene MIR137 acts as a hippocampal gene network node orchestrating the expression of genes relevant to nervous system development and function.

Journal Article

Prog Neuropsychopharmacol Biol Psychiatry, 73 , pp. 109-118, 2017, ISSN: 0278-5846.

Abstract | Links:

60 entries « 1 of 12 »

Active projects

  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre thématique de recherche en neurosciences, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1999-06-01 to 2020-10-18
  • Étude in vivo du rôle des microARNs dans la maladie d'Alzheimer et démences connexes, Subvention, Fonds de recherche du Québec - Santé, Chercheur-boursier Juniors 1 et 2, Seniors, from 2014-07-01 to 2018-06-30
  • microRNA-132: from underlying mechanism of neurodegeneration to therapeutic application in Huntington’s disease, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2017-04-01 to 2022-03-31

Recently finished projects

  • 1st Canadian Alzheimer's Disease Research Symposium (CANAD 2016), Subvention, Instituts de recherche en santé du Canada, from 2016-09-01 to 2017-08-31
  • 2nd Canadian Alhheimer's Disease Basic Research Symposium_CANAD 2016, Subvention, Société Alzheimer du Canada, 2016 Conférence Support Application, from 2016-10-01 to 2017-09-30
  • Consortium pour l'identification précoce de la Maladie d'Alzheimer - Québec (CIMA-Q)., Subvention, Fonds de recherche du Québec - Santé, Fonds d'innovation Pfizer-FRQS: sur la maladie d'Alzheimer et les maladies apparentées, from 2014-01-01 to 2017-03-31
  • Grant-in-Aid - Canad 2016, Subvention, Michael Smith Foundation for Health Research, from 2016-09-01 to 2016-12-31
  • GWAS in AD : focus on microRNA, Subvention, Instituts de recherche en santé du Canada, Subvention catalyseur: Initiative COEN, from 2015-12-01 to 2017-11-30
  • Human inducible pluripotent stem cells (IPSC) plateform, Subvention, La Fondation Neuro Canada / Brain Canada, Soutien aux plateformes technologiques (SSPT), from 2015-04-01 to 2018-03-31
  • MicroRNA 132 replacement therapy for Alzheimer's disease in a mouse model., Subvention, Société Alzheimer du Canada, Subventions de recherche, from 2015-07-01 to 2017-06-30
  • MicroRNA-15 dysregulation in sporadic Alzheimer's disease : testing the "multiple hit" hypothesis in neurodegenerative disorders, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2012-10-01 to 2018-03-31
  • Thérapie génique de remplacement de miARN pour la maladie d’Alzheimer. (fonds 0493), Subvention, Fondation de l'Université Laval, from 2014-11-05 to 2016-11-04
Data provided by the Université Laval research projects registery